Login / Signup

Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.

G Aaron HobbsNicole M BakerAnne M MiermontRyan D ThurmanMariaelena PierobonTimothy H TranAndrew O AndersonAndrew M WatersJ Nathaniel DiehlBjoern PapkeRichard G HodgeJennifer E KlompCraig M GoodwinJonathan M DeLibertyJunning WangRaymond W S NgPrson GautamKirsten L BryantDominic EspositoSharon L CampbellEmanuel F PetricoinDhirendra K SimanshuAndrew J AguirreBrian M WolpinKrister WennerbergRushikesh SableAdrienne D CoxChanning J Der
Published in: Cancer discovery (2019)
Allele-specific signaling by different KRAS alleles remains poorly understood. The KRAS G12R mutation displays uneven prevalence among cancers that harbor the highest occurrence of KRAS mutations: It is rare (∼1%) in lung and colorectal cancers, yet relatively common (∼20%) in pancreatic ductal adenocarcinoma (PDAC), suggesting context-specific properties. We evaluated whether KRASG12R is functionally distinct from the more common KRASG12D- or KRASG12V-mutant proteins (KRASG12D/V). We found that KRASG12D/V but not KRASG12R drives macropinocytosis and that MYC is essential for macropinocytosis in KRASG12D/V- but not KRASG12R-mutant PDAC. Surprisingly, we found that KRASG12R is defective for interaction with a key effector, p110α PI3K (PI3Kα), due to structural perturbations in switch II. Instead, upregulated KRAS-independent PI3Kγ activity was able to support macropinocytosis in KRASG12R-mutant PDAC. Finally, we determined that KRASG12R-mutant PDAC displayed a distinct drug sensitivity profile compared with KRASG12D-mutant PDAC but is still responsive to the combined inhibition of ERK and autophagy. SIGNIFICANCE: We determined that KRASG12R is impaired in activating a key effector, p110α PI3K. As such, KRASG12R is impaired in driving macropinocytosis. However, overexpression of PI3Kγ in PDAC compensates for this deficiency, providing one basis for the prevalence of this otherwise rare KRAS mutant in pancreatic cancer but not other cancers.See related commentary by Falcomatà et al., p. 23.This article is highlighted in the In This Issue feature, p. 1.
Keyphrases
  • wild type
  • oxidative stress
  • cell death
  • risk factors
  • cell proliferation
  • emergency department
  • dendritic cells
  • risk assessment
  • transcription factor
  • drug delivery
  • cancer therapy
  • pi k akt
  • deep learning